JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8566 GSK744 (S/GSK1265744)

Summary: HIV integrase inhibitor, oral active and long-acting

insoluble in H2O; insoluble in EtOH; ≥19.35 mg/mL
B5856 GSK1349572 sodiuM salt

Summary: Next-generation HIV integrase (IN) inhibitor

insoluble in H2O; insoluble in EtOH; ≥8.06 mg/mL
C4787 Equisetin

Summary: HIV-1 integrase inhibitor

Soluble in DMSO;Soluble in dimethyl formamide
B1122 Nelfinavir

Summary: HIV-1 protease inhibitor

insoluble in H2O; ≥16.1 mg/mL
A4069 BMS-707035

Target: HIV Integrases

Summary: HIV-I integrase inhibitor,potent and specific

insoluble in EtOH; insoluble in H2O; ≥41 mg/mL
A4070 Elvitegravir (GS-9137)

Target: HIV Integrases

Summary: HIV-1 integrase inhibitor,potent

insoluble in H2O; insoluble in EtOH; ≥20.35 mg/mL
A4071 Fluorouracil (Adrucil)
3 Citation

Target: Thymidylate Synthase

Summary: Antitumor agent;inhibitor of thymidylate synthase

insoluble in EtOH; ≥10.04 mg/mL
A4072 MK-2048

Summary: Integrase inhibitor for HIV-1,second generation

≥10.55 mg/mL

insoluble in H2O
A4073 Raltegravir (MK-0518)
1 Citation

Target: integrase

Summary: HIV-1 integrase inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.95 mg/mL
A4074 S/GSK1349572

Summary: HIV integrase inhibitor, novel and potent

≥41.9 mg/mL